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Abstract
Objective: To evaluate the sensitivity of electrical impedance myography (EIM)
to disease progression in both ambulatory and non-ambulatory boys with
DMD. Methods and Participants: A non-blinded, longitudinal cohort study of
29 ambulatory and 15 non-ambulatory boys with DMD and age-similar healthy
boys. Subjects were followed for up to 1 year and assessed using the Myolex
mViewTM EIM system as part of a multicenter study. Results: In the ambulatory group, EIM 100 kHz resistance values showed significant change compared
to the healthy boys. For example, in lower extremity muscles, the average
change in EIM 100 kHz resistance values over 12 months led to an estimated
effect size of 1.58. Based on these results, 26 DMD patients/arm would be
needed for a 12-month clinical trial assuming a 50% treatment effect. In nonambulatory boys, EIM changes were greater in upper limb muscles. For example, biceps at 100kHz resistance gave an estimated effect size of 1.92 at
12 months. Based on these results, 18 non-ambulatory DMD patients/arm
would be needed for a 12-month clinical trial assuming a 50% treatment effect.
Longitudinal changes in the 100 kHz resistance values for the ambulatory boys
correlated with the longitudinal changes in the timed supine-to-stand test. EIM
was well-tolerated throughout the study. Interpretation: This study supports that
EIM 100 kHz resistance is sensitive to DMD progression in both ambulatory and
non-ambulatory boys. Given the technology’s ease of use and broad age range of
utility it should be employed as an exploratory endpoint in future clinical therapeutic
trials in DMD. Trial Registration: Clincialtrials.gov registration #NCT02340923

Introduction
Duchenne muscular dystrophy (DMD) remains a devastating disease with limited therapeutic options. One key challenge to identifying therapy efficacy is the limited
availability of sensitive and objective measures for evaluating the drug response throughout the disease course. For
example, the 6-minute walk test (6MWT) has been one of
the standard outcome measures.1 It generally shows
improving or stable values until approximately 7 years in
4

boys with DMD2 and cannot be used in non-ambulatory
children, restricting its use to a narrow age range. Other
functional outcome measures are hindered by requiring
subjective evaluations by the evaluators and/or dependence
on task completion.3 Moreover, measuring progression in
non-ambulatory children is also difficult given the small
set of similarly limited outcome measures available.4,5
A basic approach for circumventing these issues is to
use biomarkers that neither rely on subjective assessments
nor are impacted by motivation.6 While these include
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muscle biopsy7 and blood-based analytes,8 imaging
approaches can also be used.9,10 For example, muscle
magnetic resonance imaging (MRI) is sensitive to disease
progression;11 quantitative ultrasound also shows promise.10 Yet MRI is expensive, challenging to scale, and
inconvenient; ultrasound likewise requires image system
standardization and specific training to perform.12
Another technology offering promise as a potential therapy-response biomarker is electrical impedance myography
(EIM). In EIM, a weak, high-frequency electrical current is
applied across a muscle of interest and the resulting voltages measured.13 Changes in the voltage characteristics
provide insights into the health and integrity of the muscle,
the impact of disease, and the effect of therapy.14 Several
studies have shown that EIM has high inter- and intrarater reliability.15–17 It has practical advantages as well.
EIM only takes seconds to perform, is painless, less expensive relative to standard imaging options, and is minimally
impacted by respiratory status or body contractures. In
DMD, a single-site longitudinal study provided evidence
that EIM parameters are sensitive to disease progression as
well as to the beneficial effects of corticosteroid therapy.18
However, that study, as well as a subsequent reanalysis of
the data, using more advanced analytical approaches19,
were limited since that study utilized an off-the-shelf impedance-measuring system not intended for muscle assessment and did not assess non-ambulatory boys.
Here we report results from a multisite, longitudinal
cohort DMD study exploring a dedicated EIM device to
assess DMD progression, with a focus on identifying a
single EIM parameter sensitive to disease progression
across a wide age range regardless of ambulatory status.

Methods
General
We performed a five-site multicenter study including Boston
Children’s Hospital, Washington University in St. Louis,
Colorado Children’s Hospital, Cincinnati Children’s Hospital, and Skulpt/Myolex, Inc. Four clinical sites enrolled both
healthy and DMD boys, while the Skulpt/Myolex site only
enrolled healthy boys. Institutional review board approval
was obtained at each of the five sites. Parental written
informed consent and participant verbal or written assent
was also acquired for all participants. The dates of recruitment and data collection were 31 March 2014–27 June 2016.

Participants
DMD boys
All boys were required to have genetic confirmation of
disease or to have a brother with genetically confirmed
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DMD and a characteristic clinical picture. DMD boys
were excluded if they were enrolled in a therapeutic clinical trial or had a concomitant condition that substantially
impacted health. Boys were enrolled regardless of corticosteroid use or ambulatory status.
Healthy boys
Healthy boys had no history of neuromuscular disease or
any other disorder that would be anticipated to affect
muscle health and were recruited via IRB-approved advertisement and word-of-mouth.

Study design
Study visits included baseline (0), 3, 6, and, 12 months.
At each visit, medications were reviewed, interim medical
history obtained, and weight and height measured. In
addition to the EIM measurements, a standard set of ageand ability-appropriate motor function tests were also
performed in the DMD boys only. We sought to enroll
approximately 60 boys with DMD and 60 healthy controls, all between the ages of 5 and 17, based on initial
sample size estimates.

EIM measurements
EIM was performed using the Myolex mView system
(Myolex (formally Skulpt), Inc, Boston, MA); see Figure 1,
consisting of a handheld EIM device with disposable electrode pads. Each electrode array contains three electrodepaired configurations, and thus three sets of data are
obtained virtually simultaneously across 41 applied electrical current frequencies between 1 kHz and 10 MHz.
The handheld device is connected via a cable to a power
convertor box, which itself is directly connected to a laptop. After wetting the skin with saline, the electrode array
is applied and an EIM measurement taken. This entire
process is briefly repeated two times on each muscle to
ensure stability/consistency of the data. Seven muscles
were studied unilaterally: lateral deltoid, biceps brachii,
forearm flexors, forearm extensors, quadriceps, tibialis
anterior, and medial gastrocnemius. The right side was
chosen for measurement unless clear left side dominance
was present, in which case the left side was measured. All
evaluators were trained in proper use of the system.

Functional measurements
In addition to EIM data, several functional measures were
assessed longitudinally in the DMD boys where possible.
These included: the 6MWT,1 North Star Ambulatory
Handheld
Dynamometry
(HHD)20
Assessment,9
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Figure 1. (A) mView system utilized in this study, including handheld device and electrode array (B) mView system is being applied to a young
healthy boy.

performed unilaterally using a standard HHD device on
the corresponding muscles to those assessed with EIM,
the timed supine-to-stand test,21 and the Brooke upper
extremity scale.22

Data analysis
Preliminary data processing
Prior to a formal data analysis, raw multifrequency EIM
data were assessed for artifacts, or other technical factors
negatively impacting data quality, using an automated
algorithm. This algorithm was sensitive to noise across
the frequency spectrum, and to extreme or negative values
at low frequencies (under 30 kHz) typical of poor electrode contact.
As our goal was to assess the potential for EIM parameters to effectively assess the disease progression in both
ambulatory and non-ambulatory children over a period
out to 1-year, prior to the data analysis we removed data
from children who switched steroid or ambulatory status.
Extensive reliability testing (inter and intra-rater) has
been performed previously for EIM across a variety of
disease indications including specifically in DMD,15,18 and
thus we chose not to repeat that analysis here.
Longitudinal analysis was performed using a linear
mixed effects model with random intercept and slope
terms to account for within-subject correlations and
between-subject variability under the missing-at-random
assumption. The main result of interest was the slope difference between healthy and DMD boys, since this would
enable sample size estimation (effect sizes). Univariate

6

correlations were also performed comparing EIM parameter changes with functional changes in the DMD boys out
to 1 year. Thus, our main focus was to identify those
EIM parameters that showed the largest effect sizes,
thereby providing the greatest sensitivity to disease-related
change and enabling the use of smaller patient sample
sizes. We then sought to determine whether these EIM
parameters correlated with known functional measures.
A total of 40 different EIM parameters were selected
for assessment (across frequencies, electrode configurations, and impedance features) for 10 different muscles/
muscle combinations (i.e., seven individual muscles plus
upper, lower, and whole-body averages), resulting in a
total of 400 possible outcomes assessed per patient/subject
visit.
Missing data were not imputed, and all measurements
were included. Sample size estimates for a potential clinical trial were obtained using the effect sizes observed in
our current study. Specifically, for EIM analyses, effect
size was computed as (mean slope difference)/(slope difference standard deviation), where the difference is
between the healthy and DMD boys. For our sample size
calculations, we assumed that the EIM measurements
would be obtained every 3 months and modeled 80%
power to identify significant differences between the two
groups at 12 months with P < 0.05.

Results
Table 1 shows the demographic data for the DMD and
age-matched healthy control subjects used in the
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following analyses. Figure 2, a CONSORT flowchart, summarizes the overall enrollment for the study. A total of 53
DMD boys and 57 healthy controls were initially screened
and enrolled. However, six ambulatory boys who changed
steroid status over the course of the study and three boys
who changed ambulatory status over the course of the
study were excluded from the analysis. We divided the
remaining group of DMD boys into two cohorts for analysis: an ambulatory cohort of 29 DMD boys stably on or
off steroids and a non-ambulatory cohort of 15 DMD
boys (stably on or off steroids).
Fifty-seven healthy age-similar controls were also
recruited across the five sites and enrolled over the same
time period. Forty four of them were matched to the
ambulatory boys and 13 to the non-ambulatory boys,
based on age.
Importantly, due to unexpected funding limitations,
the study was terminated prematurely, allowing only a
subset of the children to complete all 12 months, as indicated in the CONSORT flow chart.

System tolerability/adverse events
There were no serious or relatable adverse events in the
entire study and all children tolerated the EIM procedure
well.

Exclusion of data due to artifact/noise
About 3.0% of EIM data were excluded due to artifact
detected by our automated algorithm prior to analysis.

Overall results
We first sought to determine the significant differences in
EIM parameter slopes between DMD and healthy boys to
establish the sensitivity of different EIM parameters to
disease-related change. Table 2 shows the number of
parameters with different longitudinal slope values at different levels of significance. The ambulatory children
showed many significantly different EIM parameters when
comparing slopes with healthy boys (approximately 38%
of the EIM parameters assessed), whereas the number of

significantly different EIM parameters was smaller in the
non-ambulatory group.
The longitudinal changes (slopes) in the 50 and
100 kHz resistance values assessed across muscles/muscle
groups were found to be significantly different from the
changes in the muscles of age-similar healthy controls
(P < 0.05) across all four groups (ambulatory and nonambulatory at 6 and 12 months), with a slightly higher
number of muscles showing significant changes in the
100 kHz values. Accordingly, for purposes of the analysis
that follows we focused on this EIM parameter since it
appeared to be the most robust and sensitive to DMD-related muscle changes across disease state out of the various EIM parameters we explored.

EIM outcomes
Twenty-nine ambulatory DMD boys with mean age
(range) 8.65 (5.89–12.37) years and 44 healthy controls
with 8.65 (5.03–12.81) years had data included out to
6 months and, given the funding issues noted above, we
were also able to obtain 12-month data for seven ambulatory DMD boys and 10 healthy controls out of these original cohorts. For the non-ambulatory data set, 15 DMD
boys (14.40 (9.57–17.01) years) and 13 healthy boys (14.9
(13.52–16.93) years) were included in the 6-month analysis; and out of these five DMD boys and four healthy
controls contributed data at 12 months.
Tables 3 and 4 shows the differences in the rate of
change in the resistance slope comparing the DMD to
healthy boys for the 100 kHz resistance parameter over 6
and 12 months. Based on these differences, the effect sizes
and needed sample sizes for a potential clinical trial using
the 100 kHz resistance measure can be calculated, and
these are also shown in Tables 3 and 4 for both the
ambulatory and non-ambulatory cohorts. Significant differences are present in the upper extremity muscles of the
non-ambulatory boys, whereas the ambulatory boys show
the greatest differences in lower extremity muscles. In the
non-ambulatory boys, while many muscles differed
between boys with DMD and controls, only the 100 kHz
resistance in biceps data shows significance in both the 6and 12-month analyses.

Table 1. Demographic data for the ambulatory and non-ambulatory DMD and age similar healthy control cohorts.

N
Mean Age (range)
Height + S.D. (in)
Weight + S.D. (kg)
% Steroid

Ambulatory Cohort

Age Similar Healthy Controls

Non-ambulatory Cohort

Age Similar Healthy Controls

n = 29
8.65 (5.89–12.37)
122.39  8.75
31.84  14.79
100%

n = 44
8.65 (5.03–12.81)
134.33  14.36
31.25  11.79
0

n = 15
14.40 (9.57–17.01)
N/A
57.51  19.96
100%

n = 13
14.9 (13.52–16.93)
171.75  7.65
64.42  21.82
0
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Figure 2. CONSORT diagram showing flow of patients in the study.

Table 2. Rates of significance out of the 40 EIM parameters 9 10
muscle groups evaluated when comparing longitudinal EIM slopes for
DMD vs healthy boys.
Ambulatory

P
P
P
P

<
<
<
<

0.05
0.01
0.001
0.0001

Non-Ambulatory

6 months

12 months

6 months

12 months

132
85
45
17

151
99
56
22

4
0
0
0

17
4
0
0

We note that resistance values increase over time in the
DMD boys and decrease in the healthy subjects (Figs. 3
and 4), so the observed slope differences correspond to a
combination of both effects. For example, for the 12month ambulatory analysis, the seven muscle average

8

slope in DMD boys is 0.0617 (S.E. +/ 0.0166) whereas
that for healthy boys is 0.0232 (S.E. +/ 0.0141). Similarly, for the non-ambulatory boys, biceps slope in DMD
boys is 0.0529 (S.E. +/ 0.0302) and that for healthy boys
is 0.0858 (S.E. +/ 0.0316).

Functional changes and correlations
In the ambulatory DMD cohort, neither the North Star
Ambulatory Assessment nor the 6-MWT showed significant change over 6 months or 1 year compared to
baseline (North Star, baseline 24.8  6.4 points,
23.3  8,9 points at 1 year, 6-MWT, 397  71 m baseline, 398  68 m at 1 year). However, the supine-to-stand test showed significant worsening at both
6 months and 1 year (baseline, 4.7  2.0s, 6 months
5.7  2.9s,
1 year
5.0  1.6s),
P = 0.0004
and
P = 0.026, respectively.
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Table 3. 100 kHz resistance slope differences (+standard errors), effect sizes, and sample size estimates for a 6-month clinical trial at 50% and
25% treatment effects
Measure

Slope difference (+S.E.)

6-month analyses Ambulatory
Seven muscle average
0.0876 (0.0260)
Lower muscle average
0.1201 (0.0314)
Upper muscle average
0.0609 (0.0287)
Quads
0.1482 (0.0337)
Tibialis
0.1115 (0.0304)
Gastroc
0.0561 (0.0389)
Wrist extensors
0.1021 (0.0286)
Wrist flexors
0.0864 (0.0340)
Biceps
0.0334 (0.0392)
Deltoid
0.0238 (0.0492)
6-month analyses Non-ambulatory
Seven muscle average
0.0426 (0.0445)
Lower muscle average
0.0440 (0.0638)
Upper muscle average
0.0350 (0.0532)
Quads
0.0018 (0.0693)
Tibialis
0.0045 (0.0740)
Gastroc
0.1629 (0.1130)
Wrist extensors
0.0492 (0.0760)
Wrist flexors
0.0687 (0.0652)
Biceps
0.1321 (0.0630)
Deltoid
0.0712 (0.0813)

Slope difference P-value

Effect size

0.0011
0.0002
0.037
0
0.0006
0.1539
0.0006
0.0133
0.3977
0.6296

0.7904
0.8975
0.4936
1.0224
0.8843
0.3389
0.8361
0.589
0.1987
0.1119

101
78
258
61
81
547
90
181
1590
5017

403
312
1031
241
322
2188
360
724
6360
20067

0.3436
0.4939
0.5131
0.9791
0.9521
0.1619
0.5242
0.2974
0.0412
0.3854

0.3559
0.2561
0.2446
0.0103
0.024
0.5601
0.2498
0.3973
0.784
0.3251

496
958
1050
592310
109395
201
1007
398
103
594

1983
3830
4200
2369238
437577
801
4025
1592
409
2376

We performed a correlation analysis for the entire
ambulatory cohort between longitudinal changes (out to
12 months) in supine-to-stand and longitudinal changes
(out to 12 months) in 100 kHz resistance across muscles
and muscle groups. We identified highly significant correlations between longitudinal changes in supine-to-stand
and resistance for both individual muscles and muscle
groups, with the highest correlation (R = 0.644,
P = 0.00068) between supine-to-stand and the 100 kHz
resistance seven muscle average.
The only functional measure assessed longitudinally in
the older boys was the Brooke upper limb assessment.
This showed little-to-no change over the 6- or 12-month
periods in the majority of boys. Thus, we did not pursue
a correlation analysis between EIM measures and Brooke
scores.

Baseline differences based on longitudinal
mixed effect model
In the ambulatory DMD boys, at baseline the 100 kHz
resistance values were uniformly higher than those of
controls in all muscles studied (as above in Figure 4),
although those values reached significance in only a small
subset of muscles (e.g., quadriceps of 5.45  0.36 vs.
4.50  0.29 ohms, P = 0.042 for DMD vs. healthy boys).
In contrast, in the non-ambulatory boys, there were significant differences across virtually all muscles studied at

Sample size at 50%

Sample size at 25%

baseline, with the DMD boys again having higher values
(e.g., quadriceps 13.40  0.43 ohms vs. 8.70  0.44
ohms, P < 0.0001 for DMD vs. healthy boys).

Discussion
This study extends our original observations that EIM is
sensitive to changes over time in DMD across multiple
ages and stages of disease (ambulatory to non-ambulatory) and when performed by different investigators
across institutions. In addition, we identified specific EIM
parameters that (1) differentiated healthy boys from
DMD boys at baseline, (2) were sensitive to disease-related change over time with large effect sizes (and thus
excellent potential power to detect drug effects in a clinical trial), and (3) correlated to meaningful functional
change over time. The sample size estimations included
here parallel both those identified in the earlier single-site
study of EIM18 and those identified for MRI.11
A key finding of these studies is that 100 kHz resistance
— in lower limb muscles (especially quadriceps and tibialis anterior) for ambulatory boys and upper limb muscles (especially biceps brachii) for non-ambulatory boys
— is the most sensitive and reliable EIM-based measure
of DMD disease progression across disease stage. Further
assessment of this EIM parameter as a sensitive measure
of disease progression and potentially treatment effect will
be very valuable in future studies. Resistance values not
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Table 4. 100 kHz resistance slope differences (+/
and 25% treatment effects.
Measure

Slope Difference (+S.E.)

12-month analyses Ambulatory
Seven muscle average
0.0849
Lower muscle average
0.1025
Upper muscle average
0.0637
Tibialis
0.0912
Quads
0.1383
Gastroc
0.0529
Wrist extensors
0.1028
Wrist flexors
0.0764
Biceps
0.0365
Deltoid
0.0355
12-month analyses Non-ambulatory
Seven muscle average
0.0567
Lower muscle average
0.0643
Upper muscle average
0.0510
Quads
0.0110
Tibialis
0.0413
Gastroc
0.1117
Wrist extensors
0.0885
Wrist flexors
0.0245
Biceps
0.1387
Deltoid
0.0784

M. L. Leitner et al.

standard errors), effect sizes, and sample size estimates for a 12-month clinical trial at 50%

Slope Difference P-value

Effect Size

Sample Size at 50%

Sample Size at 25%

(0.0217)
(0.0234)
(0.0253)
(0.0206)
(0.0284)
(0.0314)
(0.0243)
(0.0273)
(0.0306)
(0.0446)

0.0002
0
0.0145
0
0
0.0998
0
0.0077
0.2415
0.4298

1.2137
1.5838
0.7801
1.7724
1.7233
0.6315
1.3288
1.0135
0.4192
0.2551

43
26
104
20
22
158
36
62
358
965

171
101
413
80
85
630
143
245
1430
3859

(0.0349)
(0.0526)
(0.0375)
(0.0570)
(0.0612)
(0.0829)
(0.0531)
(0.0461)
(0.0438)
(0.0562)

0.1194
0.2375
0.179
0.8486
0.5078
0.2057
0.1136
0.5981
0.0027
0.1689

0.9631
0.7004
0.827
0.1088
0.3783
0.7703
0.9557
0.3283
1.919
0.8353

68
129
92
5301
439
106
69
583
18
90

271
513
368
21201
1756
424
276
2331
69
360

Figure 3. Example of longitudinal differences in EIM Resistance values at 100 kHz averaged across seven muscles for DMD ambulatory vs agesimilar healthy control cohorts over 6 months, R = 0.088 (0.026), P = 0.0012 (left) and 12 months, R = 0.085 (0.022), P = 0.00025 (right).

only reflected differences in disease progression between
the two groups; in the ambulatory boys the changes over
time (as measured by slope) also correlated significantly
across several muscles with the supine-to-stand test.
Importantly, other EIM parameters also show disease
change. As noted in Table 2, for the ambulatory cohort
well over 100 EIM parameter-muscle pairs demonstrated
significant differences in longitudinal trajectories in
healthy versus DMD boys. These parameters included single and multifrequency reactance and phase values, as well

10

as other resistance-related parameters. However, many of
these parameters did not reach significance in the admittedly small non-ambulatory cohort comparisons. Given
the relatively small patient numbers in both non-ambulatory DMD and age-similar healthy cohorts out to 12months, and the known disease heterogeneity, this is perhaps not surprising. It remains conceivable that these
parameters could still fare well in a larger study and
could be valuable for detecting drug-related effects on
DMD muscle.
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Figure 4. Example of multifrequency resistance data of a DMD boy (right) and similarly aged healthy boy (left) measured over time in both upper
(deltoid) and lower (vastus lateralis) limb muscles, in order to provide a qualitative sense as to how the multifrequency data changes over time.
Note markedly different baseline values and increasing resistance in the DMD example with stable or slightly decreasing resistance in the healthy
example (baseline curves are in blue vs 6- and 12-month curves). As supported by the cohort data presented in Tables 3 and 4, the relatively
larger change between 0 and 6 months as compared to the relatively smaller change between 6 and 12 months in this particular boy with DMD
is not representative of the entire group.
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Compared to off-the-shelf impedance devices, the array
used for this study was designed to capture muscle-related
effects on impedance signals and to be less impacted by
subcutaneous fat.23 Intramuscular fat deposition will
increase resistance values and it is likely this, in combination with a loss of myofibers, that is contributing to the
observed change in EIM parameters. We have also
observed changes in resistance in recent EIM studies in
the D2-mdx mouse which, unlike the standard mdx
mouse, develops substantial fat infiltration of muscle.24
Changes in EIM-based resistance values are likely not
specific to DMD and are likely to occur in other neuromuscular diseases characterized by increased intramuscular fat and myofiber loss.
Resistance tends to be the most stable of the impedance
measurements, since at 100 kHz it is about 109 the value
of the measured reactance. While it remains to be determined whether resistance at 100 kHz will ultimately be
the most robust EIM parameter for determining candidate therapeutic efficacy in future DMD clinical studies,
analyzing resistance across lower limb muscles in ambulatory boys and across upper limb muscles in non-ambulatory boys represents a useful starting point.
In the earlier study18 that was neither optimized for
clinical use nor for measuring muscle impedance rather
than fat, 100kHz resistance was not as robust as some of
the other EIM parameters assessed, but it did perform in
a similar manner to the current study. For example, in
that study, the 100 kHz resistance measured in six muscles also showed higher mean baseline values in boys with
DMD than healthy controls (159  5.7 ohms vs.
124  5.3 ohms, P = 0.0001) and also increased over
12 months in boys with DMD compared to decreases in
healthy subjects (+0.71  0.34 vs. 0.2  0.34 ohms/
month, P = 0.043) giving an effect size of 0.96 for a 12month study (vs. 1.2 for the seven muscle average at
12 months in this multisite study).
There were several limitations to this study, with the
most obvious of these being the limited amount of 12month data obtained. This was entirely due to the unexpected funding limitations that required us to close the
study several months earlier than anticipated and not due
to any technical or procedural concerns. For the most
part, as our results show (Tables 3 and 4), although more
limited the results of the 12-month analyses mirror the 6month analyses.
The question arises whether the missing data for the
12-month time point should be considered missing completely at random, or whether early termination of the
study also implies that the participants who contributed
12-month data were those who enrolled in the study first,
and the earliest enrollers might be a somewhat different
population than those who enroll late. Although it is
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possible that differences in the populations who completed the 6- vs. 12-month study visit could have affected
our results, we found no differences in these two cohorts
to suggest this.
Based on our data and sample size estimates, we would
recommend that 12 months be the time course of a clinical study utilizing EIM as a study outcome. While it
would be preferable to have an earlier time point, and
this would be possible using EIM, as shown in Table 3
the number of subjects necessary to reliably detect a treatment effect at 6 months would be significantly larger than
the number of subjects required at 12 months. We
selected 12 months as the recommended time point for a
relatively small clinical study with relatively liberal inclusion criteria including boys across multiple ages and
genetic backgrounds, as this was the population we tested.
However, our analyses also support the option of using
EIM and running a shorter clinical trial using a larger
population of boys.
A second major limitation was the absence of other dedicated upper extremity functional measures outside of the
Brooke. Specifically, we did not include the PUL,5 which
only became available after this study was designed. Third,
we were not able to assess the impact of steroid initiation
given the very few children who switched status during the
study. Fourth, many of the functional measures we assessed
changed minimally in both groups over the relatively short
study time duration of 6–12 months, so seeking correlations between EIM changes and functional changes over
time was a challenge. But this limitation also speaks to the
limitations in the sensitivity and high variability of several
of the current set of widely used functional measures and
suggests the need to go beyond functional measures alone
in assessing DMD progression. Finally, we have assumed
linearity and the absence of ceiling or floor effects; clearly,
the appropriateness of these assumptions can only be
determined with additional future study.
While it can be reasonably argued that these data do
not prove conclusively that EIM is sensitive to disease
progression per se, the fact that EIM parameters change
over time in a manner that is consistent with the known
ongoing pathology strongly supports this contention.
Importantly, the EIM changes also correlate with the longitudinal changes in accepted functional measures like the
timed supine-to-stand test. Furthermore, there is substantial animal data to support the strong relationship
between EIM alterations and tissue status. Finally, the fact
that EIM appears to capture muscle changes across a wide
variety of other neuromuscular diseases and morbidities
(ALS, SMA, FSHD, disuse atrophy, etc), particularly in
muscle groups affected by disease, gives us additional
confidence that the changes that EIM is detecting are due
intrinsically to DMD progression.
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EIM remains a relatively new technique and its application in DMD even more recent. Only through the incorporation of this technology into future clinical trials can
we fully understand and refine EIM’s role in DMD in
finding effective therapies for this disease. Based on our
promising results here, we encourage academic researchers and the pharmaceutical industry alike to incorporate
the use of EIM into their future DMD clinical trials.
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